JEIL PHARMACEUTICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16,640 KRW | +0.42% |
|
-0.12% | -2.69% |
| Sales 2022 | 722B 521M 41.78B | Sales 2023 | 726B 524M 42.02B | Capitalization | 249B 180M 14.42B |
|---|---|---|---|---|---|
| Net income 2022 | -13.09B -9.45M -757M | Net income 2023 | 5B 3.61M 290M | EV / Sales 2022 | 0.46 x |
| Net Debt 2022 | 22.76B 16.43M 1.32B | Net Debt 2023 | 35.51B 25.64M 2.05B | EV / Sales 2023 | 0.39 x |
| P/E ratio 2022 |
-23.4
x | P/E ratio 2023 |
49.9
x | Employees | 964 |
| Yield 2022 |
0.24% | Yield 2023 |
-
| Free-Float | 36.82% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.42% | ||
| 1 week | -0.12% | ||
| Current month | -0.36% | ||
| 1 month | -0.36% | ||
| 3 months | -1.83% | ||
| 6 months | +9.62% | ||
| Current year | -2.69% |
1 week
16 400.00
17 650.00
1 month
15 500.0019 870.00
Current year
15 500.0019 870.00
1 year
14 540.0022 800.00
3 years
14 540.0050 900.00
5 years
14 540.00119 000.00
10 years
14 540.00119 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Seok-Jae Sung
CEO | Chief Executive Officer | 63 | - |
Chang-Seok Lee
CTO | Chief Tech/Sci/R&D Officer | 64 | - |
Chi-Guk No
BRD | Director/Board Member | 52 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sang-Cheol Han
BRD | Director/Board Member | 48 | - |
Seok-Jae Sung
CEO | Chief Executive Officer | 63 | - |
Chi-Guk No
BRD | Director/Board Member | 52 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 16,640 | +0.42% | 14,839 |
| 29/04/24 | 16,570 | +0.98% | 17,390 |
| 26/04/24 | 16,410 | -0.06% | 23,361 |
| 25/04/24 | 16,420 | -4.70% | 107,855 |
| 24/04/24 | 17,230 | +4.42% | 74,457 |
End-of-day quote Korea S.E., April 29, 2024
More quotes
JEIL PHARMACEUTICAL CO.,LTD is a Korea-based company principally engaged in the manufacturing and distribution of pharmaceuticals. The Company provides anti-inflammatory painkillers, anticancer drugs, gastritis drugs, antibiotics, ulcer treatments, antidepressant drugs, pollakisuria and incontinence treatments, impetigo drugs, septicemia treatments, hyperlipidemia treatments, peripheral neuropathic pain drugs, hypertension drugs and others. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -2.69% | 175M | |
| +19.27% | 43.18B | |
| +24.05% | 23.23B | |
| +15.11% | 14.6B | |
| +38.36% | 11.5B | |
| -7.63% | 6.79B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.21% | 5.31B | |
| -2.27% | 4.81B |
- Stock Market
- Equities
- A271980 Stock
